Comparative immunogenicity of a PreS/S hepatitis B vaccine in non- and low responders to conventional vaccine

Conventional hepatitis B vaccines do not elicit adequate antibody production in 5–10% vaccinees. This trial tests the ability of a third-generation vaccine, containing PreS1 and PreS2 antigens in addition to the S antigen, to elicit seroprotective titres in documented non- and low-responders, compar...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2006-04, Vol.24 (15), p.2781-2789
Main Authors: Rendi-Wagner, Pamela, Shouval, Daniel, Genton, Blaise, Lurie, Yoav, Rümke, Hans, Boland, Greet, Cerny, Andreas, Heim, Markus, Bach, Doris, Schroeder, Manfred, Kollaritsch, Herwig
Format: Article
Language:English
Subjects:
Adult
Age
Aged
Antigens
Applied microbiology
Biological and medical sciences
Disease
Drug dosages
Female
Fundamental and applied biological sciences. Psychology
Hepatitis
Hepatitis B
Hepatitis B - prevention & control
Hepatitis B Antibodies - blood
Hepatitis B Surface Antigens - administration & dosage
Hepatitis B Surface Antigens - immunology
Hepatitis B Vaccines - administration & dosage
Hepatitis B Vaccines - adverse effects
Hepatitis B Vaccines - immunology
Hepatitis B virus
Human viral diseases
Humans
Immunogenicity
Infections
Infectious diseases
Injections
Male
Mammalian cell derived PreS 1/PreS 2/S third-generation vaccine
Medical sciences
Microbiology
Middle Aged
Population
Protein Precursors - administration & dosage
Protein Precursors - immunology
Proteins
Response rates
Seroprotection
Vaccination failure
Vaccines
Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)
Viral diseases
Viral hepatitis
Yeast
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Conventional hepatitis B vaccines do not elicit adequate antibody production in 5–10% vaccinees. This trial tests the ability of a third-generation vaccine, containing PreS1 and PreS2 antigens in addition to the S antigen, to elicit seroprotective titres in documented non- and low-responders, compared with those to a conventional vaccine. In the primary population of non-responders (
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2006.01.007